EGFR and non-small cell lung carcinoma: However, it should be noted that a worse outcome for NSCLC with EGFR exon20 insertions and brain metastases has also been described under conventional therapies, i.e. platinum-based chemotherapy and EGFR inhibitors (21), therefore brain involvement appears to be an adverse prognostic factor for this patient group under several different therapies.